糖尿病性黄斑水肿
医学
黄斑水肿
糖尿病性视网膜病变
血管内皮生长因子
血管抑制剂
眼科
贝伐单抗
视网膜
血管内皮生长因子受体
内科学
糖尿病
化疗
内分泌学
作者
Nikhil K. Mandava,Ajay E. Kuriyan,Allen C. Ho,Jason Hsu,Carl D. Regillo,Michael A. Klufas
标识
DOI:10.1097/icu.0000000000001037
摘要
Purpose of review The increasing prevalence of diabetic macular edema (DME) necessitates an updated review of treatment modalities. While the shift from laser to anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed patient outcomes, benefits of these agents are not fully realized in real-world implementation relative to the setting of controlled clinical trials. This review outlines the evolution of intravitreal anti-VEGF treatment extension protocols for DME that reflect efforts to address treatment adherence challenges while optimizing visual outcomes. Recent findings Recent studies highlight the efficacy of extended-interval dosing with anti-VEGF agents in managing DME. Trials such as RISE/RIDE, VISTA/VIVID, and LUCIDATE have established the foundation of these regimens by demonstrating sustained visual gains with continuous treatment. However, newer trials including PROTOCOL T, KESTREL/KITE, YOSEMITE/RHINE, and PHOTON have furthered this concept, revealing that less frequent dosing of various anti-VEGF agents can maintain similar visual acuity and anatomical outcomes to traditional monthly injections. Summary The reviewed findings suggest a paradigm shift in DME treatment toward less frequent anti-VEGF injections. This has significant implications for clinical practice, potentially leading to greater adherence to treatment regimens and sustained visual function in patients, while minimizing treatment burden and healthcare costs. Further investigation into the long-term effects of extended dosing intervals is required.
科研通智能强力驱动
Strongly Powered by AbleSci AI